Navigation Links
Starting on 3 drugs at time of diagnosis benefits Type 2 diabetics
Date:6/24/2013

many of which were out of the normal range.

  • Patients on triple therapy lost 2-3 pounds on average after two years while patients on conventional therapy gained 9-10 pounds.

  • Fifteen percent of patients on triple therapy experienced one episode of hypoglycemia (low blood glucose), while 46 percent of those on conventional therapy had at least one hypoglycemic event.

    Core deficits corrected

    The triple therapy combines agents that correct two core defects in type 2 diabetes the inability to respond to insulin normally (insulin resistance), and failure of insulin-secreting beta cells to produce enough insulin. Insulin is the hormone that lowers blood glucose levels. Before the study, Dr. DeFronzo and his colleagues, including co-investigator, Muhammad Abdul-Ghani, M.D., Ph.D., of UT Medicine, hypothesized that the triple therapy would produce a greater, more durable reduction in hemoglobin A1c, reduce the fluctuation in plasma glucose by decreasing both fasting and between-meal glucose levels, and prevent weight gain, which is a side effect of traditional therapy.

    Two years of normalcy

    Two years into the three-year study, it is clear that the triple therapy is accomplishing these therapeutic goals, and that beta cells are being preserved and the body is being sensitized to insulin. "These drugs are not cures, but patients are basically normal while taking them," Dr. DeFronzo said. "They are not going to develop the microvascular (blood vessel) complications as long as their blood glucose level remains within the normal range."

    3 drugs, 3 mechanisms

    The triple therapy consists of metformin, a drug that Dr. DeFronzo helped develop in the 1990s; pioglitazone, a newer class of medication for type 2 diabetes; and exenatide, another newer class of drug. Each drug works by a different mechanism, Dr. DeFronzo said. Conventional therapy is to start the patient on metformin and wh
    '/>"/>


  • Contact: Will Sansom
    Sansom@uthscsa.edu
    210-567-2579
    University of Texas Health Science Center at San Antonio
    Source:Eurekalert

    Page: 1 2 3

    Related medicine news :

    1. Study finds doctors have exaggerated fears when starting patients on insulin
    2. Tick Season Starting Early This Year
    3. Stopping and starting cancer cell cycle weakens and defeats multiple myeloma
    4. Evident Dental Laboratory Management Software Prepares US Dental Labs for New Medical Devices Tax Starting January 1st, 2013
    5. Exclusive VIE Partners Expense Reduction Training Program Starting In January 2013
    6. Expert Revivogen Provides Tips and Education to Prevent Hair Loss, Recommends Starting a Preventative Hair Loss Regimen to Stop the Condition Before it Advances
    7. Flu Levels Starting to Fall, CDC Says
    8. Passages Malibu Applauds Easier Access to Addiction Treatment Starting in 2014
    9. Psychologist Steve Wilson Announces Plans for National Humor Month Starting April 1
    10. Starting May 1, 2013 Bay Area Systems (BayAreaSystems.com) begin offering Microsoft Office 2013 Support
    11. The Accidental Pervert is offering limited edition VIP tickets starting in April
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/27/2014)... (PRWEB) November 27, 2014 Now that ... season has officially launched, Emassagechair.com has announced ... Monday Discount Event. , Negotiating on behalf of ... top massage chair brands, Emassagechair.com has generated significant buzz ... deals and biggest discounts yet. , Shoppers are excited ...
    (Date:11/27/2014)... 27, 2014 VogueQueen.com is making every ... ladies across the world. As the premier online supplier ... is proud to release a huge selection of sexy ... outfits, it is also providing many beautiful styles in ... gowns at discounted prices. , “VogueQueen.com hopes to ...
    (Date:11/27/2014)... 27, 2014 Developers and plugin specialist of ... entitled ProPip, taking FCPX to the next level. , “ProPip ... a few clicks of a mouse,” said Christina Austin, CEO ... our users will appreciate.” , With ProPip users can show ... possibilities truly endless. ProPip is great for commentaries, news casting, ...
    (Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
    (Date:11/27/2014)... At The Little Gym, we know ... as no surprise when a recent study confirmed that ... The Journal of Pediatrics found that “Promoting ... during the school years may be important not only ... study monitored two groups of children; those that were ...
    Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
    ... have, for the first time, taken adult stem cells and ... human jaw.They say the groundbreaking work may one day //lead ... suffer from temporomandibular disorders. ,The study started with ... these cells can be coaxed to become any other type ...
    ... the last half century, and officials at the ... be diagnosed with it this year.,The study, which analyzed ... ages of 30 and 50,// found what the researchers ... tanning can be dangerous to healthy skin. ,Melanoma ...
    ... and observational studies previously conducted in elderly populations ... were performed before intracoronary stents and use of ... Dr. Hanoch Hod, of Chaim Sheba Medical //Center ... consecutive patients aged 70 or older treated for ...
    ... hormone may help patients in treating a rare disorder ... metabolic abnormalities.The study's author found that the results of ... role of leptin in common metabolic conditions such as ... her colleagues found that a lab-engineered version of leptin, ...
    ... control to limit women's periods ,Seasonale, a new drug ... reduce the number of women's periods to four a year ... pills, but for longer spans of time.// ,Seasonale ... ,"For women who desire prevention of pregnancy and are comfortable ...
    ... milk chocolate, which is most commonly used in candy ... They found the same discouraging result among patients who ... suggest that milk and other dairy products somehow discourage ... chocolate. Only subjects who ate dark chocolate showed a ...
    Cached Medicine News:Health News:Solarium use is associated with an increased risk of skin cancer 2Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Obesity Hormone -' Leptin' may treat Metabolic Disorder 2Health News:New birth control to limit women's periods 2Health News:When it comes to health, all chocolates not the same. 2
    (Date:11/26/2014)... 2014  Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... The public is welcome to participate in ... BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray 2014 ... Time Location: Palace Hotel, New York CityEvent:Oppenheimer ...
    (Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
    (Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... Company"), a clinical stage biopharmaceutical company that engages ... for the treatment of inflammatory diseases and cancer, ... underwritten public offering of 3,450,000 units, with each ... common stock, par value $0.0001 per share, and ...
    Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
    ... OSLO, Norway, October 31, 2011 Oslo ... oncology. The true strength of the Norwegian cluster lies ... than the ones available to cancer patients today. ... cluster within the field of oncology, dedicated to accelerating ...
    ... Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and ... (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee ... 01 Blood Glucose Meters as the first and second ... of service as noted by the Uniform Formulary Beneficiary ...
    Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary. 2
    This radiolucent One-piece fixator permits independent mechanical adjustments of the following: Distraction/Compression, Dorsal/Palmar Translation, Radial/Ulnar Translation, Flexion/Extension....
    Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
    The Medium External Fixator has a medium Combination Clamp that connects rod to rod or pin to rod as well as a Medium Multi-Pin Clamp that connects pins to rods allowing parallel pin placement....
    ... the Pennig Minifixator, combines the advantage of secure ... tissue dissection is not necessary, since in general, ... fixation in the hand has required bridging of ... (Asche and Burny) because of the design of ...
    Medicine Products: